Retrophin (RTRX) Bullish Stance Reiterated at BMO as RE-024 Gets Accelerated Path To Market

November 11, 2016 8:37 AM EST
Get Alerts RTRX Hot Sheet
Price: $19.56 +0.26%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade RTRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BMO Capital analyst Do Kim reiterated an Outperform rating and $40 price target on Retrophin (NASDAQ: RTRX) after the company announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating RE-024.

Kim commented, "We believe the Special Protocol Agreement (SPA) for RE-024 reached with the FDA acknowledges the significant unmet need for PKAN patients, allowing a single pivotal trial to serve as the basis for registration despite only having Phase I data in healthy volunteers. We believe the implied accelerated regulatory path supports our 2018 launch and $500mn US peak sale opportunity."

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $21.07 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

BMO Capital

Add Your Comment